Page 15 - Trending022618

warm, not hot, water.7 Applying a moistur- izer soon after bathing may also help ensure your child’s skin is moisturized.2,7
5. Understand your options.
There is no cure for eczema, but there are treatment options available. EUCRISA® (cris- aborole) ointment, 2% is a steroid-free topi- cal ointment for people with mild-to-mod- erate eczema and can be used on all skin tones from face to feet, for adults and kids as young as 2 years old.8 EUCRISA is a topical treatment that works both above and below the skin to treat eczema.9 The specific way EUCRISA works is not well defined.8 It can be applied topically to the skin, including
the face. Do not use in the eyes, mouth or vagina.8 Talk to your child’s doctor to see if EUCRISA is right for your child and visit www.EUCRISA.com to learn more.
While the above tips may help you manage your child’s eczema, always be sure to talk to their doctor to help identify the best treat- ment plan. To learn more about EUCRISA,
visit www.EUCRISA.com.
IMPORTANT SAFETY INFORMATION & INDI-
CATION
Do not use EUCRISA if you are allergic to crisab-
orole or any of the ingredients in EUCRISA. EUCRISA may cause side effects including allergic
reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. If you have any of these symptoms, stop using EUCRISA and get medical help right away.
The most common side effect of EUCRISA is applica- tion site pain, such as burning or stinging.
EUCRISA is for use on skin (topical use) only. Do not use EUCRISA in your eyes, mouth, or vagina.
INDICATION
EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic der- matitis) in adults and children 2 years of age and older.
See Full Prescribing Information at EUCRISA.com.
For more information call 1-866-EUCRISA (1-866- 382-7472).
This article is sponsored by Pfizer Inc.
1 Lifschitz C. The Impact of Atopic Dermatitis on Quality of Life. Ann Nutr Metab. 2015;66(suppl 1): 24-40.
2 Bieber T. Atopic dermatitis. Dermatol. 2012;1(3);203-217.
3 Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children: European
Academy of Allergology and Clinical Immunology/ American Academy of Allergy, Asthma and Immu- nology/PRACTALL Consensus Report. J Allerg Clin Immunol. 2006;118:152-169.
4 Hanifin JM, Reed ML. A population-based survey of eczema in the United States. Dermatitis. 2007;18(2):82-91.
5 Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.
6 Oszukowska M, Michalak I, Gutfreund K, et al. Role of primary and secondary prevention in atopic dermatitis. Postep Derm Alergol. 2015;32(6):409-420.
7 Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic der- matitis. Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.
8 EUCRISA® (crisaborole). Full Prescribing Informa- tion. December 2016.
9 Jarnagin K, Chanda S, Coronado D, et al. Cris- aborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clin- ical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15(4):390-396.
JOURNAL REVIEW | 15